Table 2 JHMI/UTSMC development cohort demographics (N = 368)
From: Validation of a novel model for the early detection of hepatocellular carcinoma
HCC (n = 119)a | Non-malignant liver diseasea (n = 215) | Healthy controls (n = 34) | |||
|---|---|---|---|---|---|
Stage 1 (n = 30) | Stage 2 (n = 40) | Stage 3 and 4 (n = 49) | |||
Age (years); median (IQR) | 61.5 (56.2–67.0) | 61 (58.0–64.5) | 60 (57.0–65.5) | 54 (42.0–60.0) | 60.5 (51.2–64.8) |
Age range (years) | 45–88 | 18–85 | 45–80 | 8–75 | 40–77 |
Sex (male:female) [%] | 77:23 | 75:25 | 85:15 | 60:40 | 50:50 |
Ethnicity (%) | |||||
Caucasian | 53 | 55 | 52 | 47 | 68 |
African American | 37 | 33 | 40 | 38 | 6 |
Hispanic/Latino | 3 | 5 | 2 | 2 | 0 |
Asian | 7 | 0 | 6 | 10 | 0 |
Native American/Pacific Islander | 0 | 3 | 0 | 0 | 0 |
Other | 0 | 0 | 0 | 1 | 0 |
Unknown | 0 | 5 | 0 | 1 | 26 |
Etiology (%) | |||||
Non-viral | 27 | 28 | 29 | – | – |
HBV | 7 | 0 | 6 | ||
HCV | 53 | 65 | 52 | ||
HBV and HCV | 0 | 5 | 4 | ||
Unknown | 13 | 2 | 8 | – | – |